Deal Library / Pharma BD Deal Intelligence

Hematology Deals

The Pharma Closeout tracks 84 deals, $240.5B in disclosed deal value, 40 with a post-close Outcome Score for Hematology.

Median Critic Score: 74  ·  Median Outcome Score: 58

Best outcome: Amgen Inc. / Micromet Inc. (88)  ·  Weakest outcome: Shire plc / FerroKin BioSciences, Inc. (8)

All 84 deals

• Servier / Shire plc (Oncology Business) — 2018 · $2.4B · Worked — the deal delivered on its rationale.
• Amgen Inc. / Micromet Inc. — 2012 · $1.2B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Alexion Pharmaceuticals Inc. — 2020 · $39.0B · Worked — the deal delivered on its rationale.
• Swedish Orphan Biovitrum AB / Biovitrum — 2001 · $493M · Worked — the deal delivered on its rationale.
• AbbVie Inc. / Pharmacyclics Inc. — 2015 · $21.0B · Worked — the deal delivered on its rationale.
• Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals Inc. — 2013 · $886M · Worked — the deal delivered on its rationale.
• Shire plc / Baxalta Inc. — 2016 · $32.0B · Worked — the deal delivered on its rationale.
• Incyte Corporation / MacroGenics, Inc. — 2017 · $900M · Largely worked — most objectives met.
• Incyte Corporation / Vega Therapeutics, Inc. — 2026 · $2.0B · Largely worked — most objectives met.
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. — 2022 · $1.1B · Largely worked — most objectives met.
• Grifols, S.A. / Talecris Biotherapeutics Holdings Corp. — 2011 · $3.4B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Kite Pharma Inc. — 2017 · $11.9B · Largely worked — most objectives met.
• Agios Pharmaceuticals Inc. / Oscotec Inc. — 2026 · $165M · Largely worked — most objectives met.
• Baxalta Incorporated / Sigma-Tau Finanziaria S.p.A. (Oncaspar portfolio) — 2015 · $900M · Largely worked — most objectives met.
• Swedish Orphan Biovitrum AB / CTI BioPharma Corp. — 2023 · $1.7B · Largely worked — most objectives met.
• Merck & Co. Inc. / Imago BioSciences Inc. — 2022 · $1.4B · Largely worked — most objectives met.
• Orchard Therapeutics Limited / GlaxoSmithKline plc — 2018 · Largely worked — most objectives met.
• Jazz Pharmaceuticals plc / EUSA Pharma — 2012 · $700M · Largely worked — most objectives met.
• Nuvectis Pharma, Inc. / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $1.5B · Mixed — partial payoff, real shortfalls.
• Novo Nordisk A/S / Forma Therapeutics Holdings Inc. — 2022 · $1.1B · Mixed — partial payoff, real shortfalls.
• Bioverativ Inc. / True North Therapeutics, Inc. — 2017 · $825M · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Bioverativ Inc. — 2018 · $11.6B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Constitution Medical Investors Inc. — 2013 · $220M · Mixed — partial payoff, real shortfalls.
• Mallinckrodt plc / Therakos, Inc. — 2015 · $1.3B · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Limited / ARIAD Pharmaceuticals, Inc. — 2017 · $5.2B · Mixed — partial payoff, real shortfalls.
• Akebia Therapeutics, Inc. / Keryx Biopharmaceuticals, Inc. — 2018 · $1.3B · Underwhelmed — fell short of the thesis.
• Novartis AG / Selexys Pharmaceuticals Corporation — 2016 · $665M · Underwhelmed — fell short of the thesis.
• Novartis AG / Selexys Pharmaceuticals — 2002 · $665M · Underwhelmed — fell short of the thesis.
• Gilead Sciences, Inc. / Calistoga Pharmaceuticals, Inc. — 2011 · $600M · Underwhelmed — fell short of the thesis.
• Sanofi SA / TargeGen, Inc. — 2010 · $560M · Underwhelmed — fell short of the thesis.
• Takeda Pharmaceutical Company Ltd. / Intellikine, Inc. — 2011 · $310M · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / Global Blood Therapeutics Inc. — 2022 · $5.4B · Did not work — the deal failed to deliver.
• Sumitomo Dainippon Pharma Co., Ltd. / Tolero Pharmaceuticals, Inc. — 2016 · $780M · Did not work — the deal failed to deliver.
• Pfizer Inc. and Les Laboratoires Servier / Cellectis SA (UCART19 program) — 2015 · $338M · Did not work — the deal failed to deliver.
• F. Hoffmann-La Roche AG / Tensha Therapeutics, Inc. — 2016 · $535M · Did not work — the deal failed to deliver.
• Celgene Corporation / Avila Therapeutics, Inc. — 2012 · $925M · Did not work — the deal failed to deliver.
• Gilead Sciences, Inc. / YM BioSciences Inc. — 2012 · $510M · Did not work — the deal failed to deliver.
• CSL Behring (CSL Limited) / Calimmune, Inc. — 2017 · $416M · Did not work — the deal failed to deliver.
• Alexion Pharmaceuticals, Inc. / Syntimmune, Inc. — 2018 · $1.2B · Did not work — the deal failed to deliver.
• Shire plc / FerroKin BioSciences, Inc. — 2012 · $325M · Did not work — the deal failed to deliver.
• Liminatus Pharma, Inc. / InnocsAI, Inc. — 2026 · $320M
• Bristol-Myers Squibb Company / Jiangsu Hengrui Pharmaceuticals Co., Ltd. — 2026 · $15.2B
• Eli Lilly and Company / Kelonia Therapeutics, Inc. — 2026 · $7.0B
• Gilead Sciences Inc. / Ouro Medicines, Inc. — 2026 · $2.2B
• Eli Lilly and Company / Engage Biologics, Inc. — 2026 · $202M
• Sanofi SA / Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical Limited) — 2026 · $1.5B
• Eli Lilly and Company / Ajax Therapeutics, Inc. — 2026 · $2.3B
• Merck & Co. Inc. / Terns Pharmaceuticals, Inc. — 2026 · $6.7B
• Gilead Sciences, Inc. (via Kite) / Interius BioTherapeutics, Inc. — 2025 · $350M
• Bristol-Myers Squibb Company / 2seventy bio, Inc. — 2025 · $286M
• AstraZeneca PLC / EsoBiotec SA — 2025 · $1.0B
• Taiho Pharmaceutical Co., Ltd. / Araris Biotech AG — 2025 · $1.1B
• AbbVie Inc. / Ichnos Glenmark Innovation (IGI) — 2025 · $1.9B
• Merck & Co. Inc. / Curon Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.3B
• Recordati S.p.A. / Sanofi SA — 2024 · $1.1B
• Kyowa Kirin Co. Ltd. / Kura Oncology Inc. — 2024 · $1.5B
• AstraZeneca PLC / LaNova Medicines Limited — 2023 · $600M
• Bristol-Myers Squibb Company / Century Therapeutics Inc. — 2022 · $3.1B
• Roche Holding AG / Poseida Therapeutics Inc. — 2022 · $6.1B
• Blackstone Life Sciences / Sanofi S.A. (Sarclisa subQ co-development) — 2022 · $331M
• Ipsen S.A. / Epizyme Inc. — 2022 · $247M
• AstraZeneca PLC (Alexion) / Caelum Biosciences — 2021 · $500M
• Sanofi SA / Owkin, Inc. — 2021 · $270M
• MorphoSys AG / Constellation Pharmaceuticals, Inc. — 2021 · $1.7B
• Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG — 2021 · $1.1B
• Johnson & Johnson / Fate Therapeutics, Inc. — 2020 · $3.1B
• Alexion Pharmaceuticals Inc. / Portola Pharmaceuticals, Inc. — 2020 · $1.4B
• AbbVie Inc. / Harpoon Therapeutics, Inc. — 2019 · $510M
• Sobi (Swedish Orphan Biovitrum AB) / Dova Pharmaceuticals, Inc. — 2019 · $915M
• Roche Holding AG / Promedior, Inc. — 2019 · $1.4B
• Pieris Pharmaceuticals, Inc. / Seattle Genetics, Inc. — 2018 · $1.2B
• Genentech, Inc. (Roche Holding AG) / Affimed N.V. — 2018 · $5.1B
• Janssen (Cilag GmbH International, J&J) / argenx SE — 2018 · $1.8B
• Pfizer Inc. / Sangamo Therapeutics, Inc. — 2017 · $545M
• Incyte Corporation / Calithera Biosciences, Inc. — 2017 · $803M
• Janssen Biotech, Inc. (Johnson & Johnson) / MacroGenics, Inc. — 2016 · $740M
• Bristol-Myers Squibb Company / Promedior, Inc. — 2015 · $1.2B
• Amgen Inc. / Kite Pharma, Inc. — 2015 · $585M
• AbbVie Inc. / Infinity Pharmaceuticals, Inc. — 2014 · $805M
• GlaxoSmithKline plc / Adaptimmune Therapeutics plc — 2014 · $350M
• Pfizer Inc. / Cellectis SA — 2014 · $2.9B
• Celgene Corporation / Forma Therapeutics Holdings, LLC — 2014 · $600M
• Servier SAS / Cellectis SA — 2014 · $850M
• Ipsen SA / Inspiration Biopharmaceuticals, Inc. — 2010 · $259M

← Deal Library  ·  Interactive search  ·  How we score deals